Ken Griffin Infla Rx N.V. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.34 - $1.73 $18,894 - $24,393	14,100 Added 271.15%	19,300 $29,000
Q2 2024 Aug 14, 2024	SELL	$1.18 - $1.74 $9,086 - $13,398	-7,700 Reduced 59.69%	5,200 $9,000
Q4 2023 Feb 14, 2024	SELL	$1.25 - $2.75 $7,125 - $15,675	-5,700 Reduced 30.65%	12,900 $21,000
Q3 2023 Nov 14, 2023	BUY	$2.66 - $4.33 $28,728 - $46,764	10,800 Added 138.46%	18,600 $55,000
Q2 2023 Aug 14, 2023	SELL	$2.05 - $6.1 $11,069 - $32,940	-5,400 Reduced 40.91%	7,800 $34,000
Q1 2023 May 15, 2023	SELL	$1.66 - $3.1 $5,644 - $10,540	-3,400 Reduced 20.48%	13,200 $25,000
Q4 2022 Feb 14, 2023	SELL	$2.11 - $3.25 $29,329 - $45,175	-13,900 Reduced 45.57%	16,600 $51,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $3.14 $40,260 - $95,770	30,500 New	30,500 $81,000

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $86.2M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.